Biotechnology
Why Cooley
Breakthroughs happen with Cooley. At Cooley, we don’t just advise – we accelerate your achievements. Our collaborative approach draws upon unparalleled experience and our extensive industry network to drive strategic solutions and resolve challenges. With Cooley as your catalyst, you’re not just part of the biotech industry – you’re shaping it.
Cooley works with biotechnology companies through all stages of the business life cycle. Our experience stretches across public offerings, mergers and acquisitions, private financings, licensing, regulatory and patent counseling. Clients that partner with us get the advantage of decades of experience, seamless teamwork and an entrepreneurial culture that help build businesses and transform breakthrough ideas into successful companies.
When it comes to biotech, Cooley was there from the start. We incorporated Genentech, the first biotech company, in 1976 and worked on Amgen’s initial public offering in 1980, the first biotech IPO in history. Enter the 21st century, where Cooley remains the preeminent law firm for disruptive biotech companies and investors, leveraging our deep industry experience to provide innovative legal solutions for our clients.
Representative matters
- Chimerix Announces Acquisition by Jazz Pharmaceuticals for $935 Million
- Hummingbird Bioscience Announces Exclusive Worldwide License Agreement With Callio Therapeutics
- Aardvark Therapeutics Announces $94.2 Million IPO
- Beihai Biotech Signs Exclusive Licensing, Supply and Commercialization Agreement With Zydus
- Alumis Announces Merger With ACELYRIN
- InnoCare and KeyMed Jointly Announce License Agreement With Prolium
- Flare Therapeutics Announces Strategic Discovery Collaboration With Roche, Potentially Exceeding $1.8 Billion
- Avenzo Therapeutics Announces Exclusive Global License Agreement With DualityBio
- Tvardi Therapeutics Announces Merger With Cara Therapeutics
- SiteOne Therapeutics Announces $100 Million Series C
- Angitia Biopharmaceuticals Announces $120 Million Series C
- Keros Therapeutics Announces Ex-China Global License Agreement With Takeda
- Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion
- Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement
- Septerna Announces Upsized $331.2 Million IPO
- Archon Biosciences Announces $20 Million Seed Financing
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.